Implication of calpain in neuronal apoptosis - A possible regulation of Alzheimer's disease

被引:115
作者
Raynaud, F. [1 ]
Marcilhac, A. [1 ]
机构
[1] Univ Montpellier 2, CNRS, UMR 5539, EPHE, F-34095 Montpellier 5, France
关键词
Alzheimer's disease; apoptosis; calpain; neurodegenerative disease; neuron;
D O I
10.1111/j.1742-4658.2006.05352.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apoptotic neuronal cell death is the cardinal feature of aging and neurodegenerative diseases, but its mechanisms remain obscure. Caspases, members of the cysteine protease family, are known to be critical effectors in central nervous system cellular apoptosis. More recently, the calcium-dependent proteases, calpains, have been implicated in cellular apoptotic processes. Indeed, several members of the Bcl-2 family of cell death regulators, nuclear transcription factors (p53) and caspases themselves are processed by calpains. Progressive regional loss of neurons underlies the irreversible pathogenesis of various neurodegenerative diseases such as Alzheimer's disease in adult brain. Alzheimer's disease is characterized by extracellular plaques of amyloid-beta peptide aggregates and intracellular neurofibrillary tangles composed of hyperphosphorylated tau leading to apoptotic cell death. In this review, we summarize the arguments showing that calpains modulate processes that govern the function and metabolism of these two key proteins in the pathogenesis of Alzheimer's disease. To conclude, this article reviews our understanding of calpain-dependent apoptotic neuronal cell death and the ability of these proteases to regulate intracellular signaling pathways leading to chronic neurodegenerative disorders such as Alzheimer's disease. Further research on these calpain-dependent mechanisms which promote or prevent cell apoptosis should help us to develop new approaches for preventing and treating neurodegenerative disorders.
引用
收藏
页码:3437 / 3443
页数:7
相关论文
共 48 条
[1]   Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2 [J].
Adamec, E ;
Mohan, P ;
Vonsattel, JP ;
Nixon, RA .
ACTA NEUROPATHOLOGICA, 2002, 104 (01) :92-104
[2]  
AVILA J, 2006, FEBS LETT
[3]   Calpain inhibitors, a treatment for Alzheimer's disease - Position paper [J].
Battaglia, F ;
Trinchese, F ;
Liu, SM ;
Walter, S ;
Nixon, RA ;
Arancio, O .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2003, 20 (03) :357-362
[4]   Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12 [J].
Chan, SL ;
Culmsee, C ;
Haughey, N ;
Klapper, W ;
Mattson, MP .
NEUROBIOLOGY OF DISEASE, 2002, 11 (01) :2-19
[5]   Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion [J].
Chen, M ;
He, HP ;
Zhan, SX ;
Krajewski, S ;
Reed, JC ;
Gottlieb, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (33) :30724-30728
[6]   μ-Calpain is functionally required for α-processing of Alzheimer's β-amyloid precursor protein [J].
Chen, M ;
Fernandez, HL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 330 (03) :714-721
[7]   Stimulation of β-amyloid precursor protein α-processing by phorbol ester involves calcium and calpain activation [J].
Chen, M ;
Fernandez, HL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 316 (02) :332-340
[8]   Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases [J].
Chua, BT ;
Guo, K ;
Li, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (07) :5131-5135
[9]   CALCIUM-ACTIVATED NEUTRAL PROTEASE (CALPAIN) SYSTEM - STRUCTURE, FUNCTION, AND REGULATION [J].
CROALL, DE ;
DEMARTINO, GN .
PHYSIOLOGICAL REVIEWS, 1991, 71 (03) :813-847
[10]   Nuclear translocation of nuclear transcription factor-κB by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors leads to transcription of p53 and cell death in dopaminergic neurons [J].
de Erausquin, GA ;
Hyrc, K ;
Dorsey, DA ;
Mamah, D ;
Dokucu, M ;
Mascó, DH ;
Walton, T ;
Dikranian, K ;
Soriano, M ;
Verdugo, JMG ;
Goldberg, MP ;
Dugan, LL .
MOLECULAR PHARMACOLOGY, 2003, 63 (04) :784-790